Test Bank For Abrams’ Clinical Drug Therapy Rationales for Nursing Practice 12th Edition Geralyn Frandsen

ABRAMS' CLINICAL DRUG THERAPY: RATIONALES FOR NURSING PRACTICE

,ABRAMS'wwCLINICALwwDRUGwwTHERAPY:wwRATIONALESwwFORwwNURSINGwwPR
ACTICE

,ABRAMS'wwCLINICALwwDRUGwwTHERAPY:wwRATIONALESwwFORwwNURSINGwwPR
ACTICE

, ABRAMS'wwCLINICALwwDRUGwwTHERAPY:wwRATIONALESwwFORwwNURSINGwwPR
ACTICE

Chapterww1,wwThewwFoundationwwofwwPharmacology:wwQualitywwandwwSafety

1. Awwwomanwwdiagnosedwwwithwwobsessive–
compulsivewwdisorderwwhaswwbeenwwprescribedwworalw w paroxetinewwhydrochloride.ww
Whatww iswwthewwexpectedwweffectwwforwwthiswwprescription?
A. Curativewweffectwwonwwsymptoms
B. Systemicwweffectwwonwwsymptoms
C. Localwweffectwwonwwsymptoms
D. Parenteralwweffectwwonwwsymptoms
ANS:wwwwB
Rationale:wwDrugswwthatwwproducewwsystemicwweffectswwarewwtakenwwintowwthewwbody,wwcirculatedw
wthroughw w thewwbloodstreamwwtowwtheirwwsiteswwofwwactionwwinwwvariousww bodywwtissues,ww andwwe

ventuallywweliminatedw w fromwwthewwbody.wwCurativewwagentswwarewwgivenwwtowwcurewwawwdiseas
ewwprocess.wwInwwthiswwcase,wwparoxetinew w hydrochloridewwwillwwcontrolwwthewwsymptomswwbutww n
otwwcurewwthewwdisorder.wwDrugswwwithwwlocalwweffects,w w suchwwaswwsunscreenwwandwwlocalwwanesth
etics,wwactwwmainlywwatwwthewwsitewwofwwapplication.w w Paroxetinew w hydrochloridewwiswwnotwwadmi
nisteredwwparenterally.wwParenteralwwagentswwarewwadministeredw w subcutaneously,ww intramuscul
arly,wworwwintravenously.

PTS: 1 REF: p.ww3,wwIntroduction OBJ: 1
NAT:w w ClientwwNeeds:wwPhysiologicalwwIntegrity:wwPharmacologicalwwandwwParenteralwwTher
apiesw w TOP:
Chapter:ww1:wwThewwFoundationwwofwwPharmacology:ww QualitywwandwwSafety
KEY:w w IntegratedwwProcess:wwNursingwwProcess
BLM:www w CognitivewwLevel:wwUnderstand NOT:w w MultiplewwChoice

2. Awwclientwwhaswwbeenwwprescribedwwanwwantibiotic.wwThiswwmedicationwwiswwawwnaturallywwoccurring
substancewwthatwwhaswwbeenwwcheGmR
icA
alDlyEm
SoBdOifOieSd.TWhaOtwwM
.C iswwanotherwwnamewwforwwthiswwtypewwof
wwmedication?

A. Syntheticwwdrug
B. Semisyntheticwwdrug
C. Biotechnologywwdrug
D. Prototypewwdrug
ANS:wwwwB
Rationale:wwSemisyntheticwwdrugsww(e.g.,wwmanywwantibiotics)wwareww naturallywwoccurringwwsubsta
ncesw w thatwwhavewwbeenwwchemicallywwmodified.wwSyntheticwwdrugswwarewwmorewwstandardizedw
w inwwtheirww chemicalw w characteristics,ww morewwconsistentww inwwtheirwweffects,ww andwwlessww likelywwt

owwproducewwallergicwwreactions.w w BiotechnologywwdrugswwinvolvewwmanipulatingwwDNAwwandww
RNAwwandwwrecombiningwwgeneswwintow w hybridwwmoleculeswwthatwwcanwwbewwinsertedwwintowwlivin
gwworganisms.wwPrototypewwdrugswwarewwthewwfirstw w drugwwofwwawwparticularwwgroupwwtowwbewwd
eveloped.

PTS: 1 REF: p.ww3,wwDrugwwSources OBJ: 1
NAT:w w ClientwwNeeds:wwPhysiologicalwwIntegrity:wwPharmacologicalwwandwwParenteralwwTher
apiesw w TOP:
Chapter:ww1:wwThewwFoundationwwofwwPharmacology:wwQualitywwandwwSafety
KEY:w w IntegratedwwProcess:wwNursingwwProcess
BLM:www w CognitivewwLevel:wwUnderstand NOT:w w MultiplewwChoice

3. Whichwwclassificationwwapplieswwtowwmorphine?
A. Centralwwnervouswwsystemwwdepressant
B. Centralwwnervouswwsystemwwstimulant